Utah Medical Products UTMD Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value

Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value at other companies

UFP TechnologiesUFPT

——

Medline, Inc. MDLN

——

Other financials

Income statement

See full

Revenue$8.7M-10.2%

Gross profit$5.3M-4.6%

Operating income$2.6M-18.6%

Net income$2.6M-14.4%

EPS (diluted)$0.82-10.9%

Balance sheet

See full

Cash & equivalents$87.4M+4.9%

Total debt$210.0K—

Total equity$120.4M+2.8%

Total assets$124.4M+1.5%

Cash flow

See full

Operating cash flow$3.1M-30.4%

CapEx$130.0K-29.3%

Free cash flow$3.0M-30.4%

Valuation

See full

Market cap$219.63M+26.4%

Enterprise value$132.44M+42.5%

P/E20.3×+6.4×

P/S5.9×+1.4×

Profitability

See full

Gross margin57.9%-0.4pp

Operating margin28.8%-3.9pp

Net margin28.9%-4.1pp

FCF margin34.7%0.0pp

Returns & leverage

See full

Return on equity9.1%-1.4pp

Debt / equity0×—

Current ratio28.6×+6.3×

Where this comes from

Reported directly by Utah Medical Products in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue.

The official record: Utah Medical Products’s 10-K, filed March 27, 2026, on SEC EDGAR. View the filing →

Ask your AI about Utah Medical Products's share-based compensation arrangement by share-based payment award, options, outstanding, intrinsic value.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Utah Medical Products's share-based compensation arrangement by share-based payment award, options, outstanding, intrinsic value?: Utah Medical Products (UTMD) reported share-based compensation arrangement by share-based payment award, options, outstanding, intrinsic value of $0 in Q4 2025.
What is the long-term trend for Utah Medical Products's share-based compensation arrangement by share-based payment award, options, outstanding, intrinsic value?: Over 5 years (2020 to 2025), Utah Medical Products's share-based compensation arrangement by share-based payment award, options, outstanding, intrinsic value has grown at a -100.0% compound annual growth rate (CAGR), from $1.18M to $0.